Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis

被引:3
|
作者
Chen, Bo [1 ]
Ji, Su-Qiong [1 ]
Shen, Fan [1 ]
Tian, Dai-Shi [1 ]
Bu, Bi-Tao [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430030, Peoples R China
关键词
Relapse-associated worsening; Progression independent of relapse activity; Relapsing-onset multiple sclerosis; Mediation analysis; Onset age; NATURAL-HISTORY; CLINICAL-COURSE; AGE; OCRELIZUMAB; PROGRESSION; INTERFERON; PLACEBO; MODELS;
D O I
10.1016/j.msard.2022.103555
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: The neurological disability accumulation in patients with relapsing-onset multiple sclerosis (MS) is commonly attributed to relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). Using a mediation model, this research aimed to investigate and quantify the contributions of RAW and PIRA to the overall disability accrual.Methods: Clinical data, containing Expanded Disability Status Scale (EDSS) scores, duration, attack number, and demographics, were collected from 121 patients with relapsing-onset MS in China and included in the mediation model. Two phases were defined: an early phase, from the clinical onset to EDSS 3, and a later phase, greater than EDSS 3.Results: Clinical attack number partly mediated the relationship between duration and neurological disability (Duration-* Attack-* EDSS score) only in the early phase, with the ratio of indirect (RAW) to total effect of 0.414; while this mediator effect became negligible (<10%) in the later phase, with a predominating direct effect (PIRA). Onset age positively correlated with EDSS scores during the early stage, independent of the clinical attack number (the direct effect was significant, but the indirect effect was not), while this association was insignificant later. Besides, compared to females, male patients appeared to relapse less frequently before reaching EDSS 3 but were vulnerable to an accelerated progression after that.Conclusions: In relapsing-onset MS, PIRA is the major contributor to the irreversible disability accrual throughout the whole disease course, albeit RAW is also partly involved during the early stage. The correlations between the disabled outcome and the onset age or sex vary in different phases.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
    Kappos, Ludwig
    Wolinsky, Jerry S.
    Giovannoni, Gavin
    Arnold, Douglas L.
    Wang, Qing
    Bernasconi, Corrado
    Model, Fabian
    Koendgen, Harold
    Manfrini, Marianna
    Belachew, Shibeshih
    Hauser, Stephen L.
    JAMA NEUROLOGY, 2020, 77 (09) : 1132 - 1140
  • [2] Progression independent of relapse activity is the main determinant of disability accumulation in relapsing-onset multiple sclerosis patients
    Portaccio, E.
    Bellinvia, A.
    Addazio, I.
    Betti, M.
    Ballerini, C.
    Pasto, L.
    Razzolini, L.
    Totaro, R.
    Spitaleri, D.
    Lugaresi, A.
    Cocco, E.
    Onofrj, M.
    Di Palma, F.
    Patti, F.
    Maimone, D.
    Valentino, P.
    Confalonieri, P.
    Protti, A.
    Sola, P.
    Lus, G.
    Maniscalco, G. T.
    Morra, V. Brescia
    Salemi, G.
    Granella, F.
    Pesci, I.
    Bergamaschi, R.
    Aguglia, U.
    Vianello, M.
    Simone, M.
    Lepore, V.
    Iaffaldano, P.
    Filippi, M.
    Trojano, M.
    Amato, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 440 - 442
  • [3] Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras
    Montobbio, Noemi
    Cordioli, Cinzia
    Signori, Alessio
    Bovis, Francesca
    Capra, Ruggero
    Sormani, Maria Pia
    ANNALS OF NEUROLOGY, 2025, 97 (01) : 95 - 103
  • [4] NATALIZUMAB REDUCES RELAPSE-ASSOCIATED COSTS OF HOSPITALIZATIONS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    O'Day, K.
    Meyer, K.
    Rajagopalan, K.
    VALUE IN HEALTH, 2008, 11 (06) : A605 - A605
  • [5] Disability accrues as relapse associated worsening in Apolipoprotein E4 relapsing multiple sclerosis patients
    Aprea, Maria Grazia
    Portaccio, Emilio
    Betti, Matteo
    De Meo, Ermelinda
    Pasto, Luisa
    Razzolini, Lorenzo
    Prestipino, Elio
    Masciulli, Camilla
    Ballerini, Chiara
    Nacmias, Benedetta
    Sorbi, Sandro
    Amato, Maria Pia
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 224 - 224
  • [6] Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies
    Kappos, L.
    Wolinsky, J. S.
    Giovannoni, G.
    Arnold, D. L.
    Wang, Q.
    Bernasconi, C.
    Model, F.
    Manfrini, M.
    Belachew, S.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 256 - 257
  • [7] "Hidden" symptoms drive progression independent of relapse activity in relapsing-onset multiple sclerosis patients
    Portaccio, E.
    Fonderico, M.
    Aprea, M. G.
    Masciulli, C.
    Cecconi, E.
    Pasto, L.
    Razzolini, L.
    Totaro, R.
    Spitaleri, D.
    Lugaresi, A.
    Cocco, E.
    Onofrj, M.
    Di Palma, F.
    Patti, F.
    Maimone, D.
    Valentino, P.
    Confalonieri, P.
    Protti, A.
    Sola, P.
    Lus, G.
    Maniscalco, G. T.
    Morra, V. Brescia
    Salemi, G.
    Granella, F.
    Pesci, I.
    Bergamaschi, R.
    Aguglia, U.
    Vianello, M.
    Simone, M.
    Lepore, V.
    Iaffaldano, P.
    Filippi, M.
    Trojano, M.
    Amato, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 166 - 167
  • [8] Relapse-associated worsening and progression independent of relapse activity in an Italian multicentre cohort of early multiple sclerosis patients
    Fonderico, M.
    Portaccio, E.
    Bellinvia, A.
    Pasto, L.
    Razzolini, L.
    Totaro, R.
    Spitaleri, D.
    Lugaresi, A.
    Cocco, E.
    Onofrj, M.
    Di Palma, F.
    Patti, F.
    Maimone, D.
    Valentino, P.
    Brambilla, L.
    Protti, A.
    Sola, P.
    Lus, G.
    Maniscalco, G. T.
    Morra, V. Brescia
    Salemi, G.
    Granella, F.
    Pesci, I.
    Bergamaschi, R.
    Aguglia, U.
    Vianello, M.
    Simone, M.
    Lepore, V.
    Iaffaldano, P.
    Filippi, M.
    Trojano, M.
    Amato, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 25 - 26
  • [9] Coagulation activation in relapsing-remitting multiple sclerosis with relapse-associated lymphopenia
    Koudriavtseva, T.
    Conti, L.
    D'Agosto, G.
    Stefanile, A.
    D'Alessandro, M. G.
    Fiorelli, M.
    Lapucci, C.
    Cellerino, M.
    Truglio, M.
    Maschio, M.
    Galie, E.
    Zannino, S.
    Salvetti, M.
    Inglese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 302 - 302
  • [10] Progression independent of relapse activity and relapse-associated worsening predict future disability on multiple clinical domains
    Tur, Carmen
    Carbonell, Pere
    Cobo Calvo, Alvaro
    Otero-Romero, Susana
    Guio-Sanchez, Claudia
    Arrambide, Georgina
    Midaglia, Luciana
    Castillo-Justribo, Joaquin
    Vidal-Jordana, Angela
    Rodriguez, Breogan
    Beltran, Jordina
    Mongay-Ochoa, Neus
    Vilaseca, Andreu
    Arino, Helena
    Zabalza, Ana
    Bollo, Luca
    Pappolla, Agustin
    Jesus Arevalo, Maria
    Galan, Ingrid
    Nos, Carlos
    Comabella, Manuel
    Rio, Jordi
    Pareto, Deborah
    Sastre-Garriga, Jaume
    Rovira Canellas, Alex
    Tintore, Mar
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 422 - 423